Drug-resistant bacteria, a looming public health disaster, have many causes, most notably the overuse of antibiotics in farm animals and overprescribing in humans. But one cause has received virtually no attention: pollution from drug manufacturing facilities producing antibiotics, which are predominantly produced in India and China.

To promote awareness and spur action, Bill and Henry wrote an op-ed that appeared in STAT with three major recommendations:

• US drug makers should require their suppliers to stop polluting.
• The FDA and other relevant US agencies should pressure their counterparts in India and China to toughen regulations.
• Major pharmaceutical retailers should use their buying power to pressure US manufacturers to clean up their foreign supply chains.

Read more on STAT.